Uveal Melanoma Treatment Market

Q: What will be the CAGR of the global uveal melanoma treatment industry during the forecast period?

The CAGR is anticipated to be 7.1% from 2025 to 2035 Read More

Uveal Melanoma Treatment Market (Therapy Type: Immunotherapy, Chemotherapy and Radiation Therapies; Treatment Approach: Monotherapy and Combination Therapy; and Location: Iris Melanoma, Ciliary Melanoma, Choroid Melanoma and Conjunctival Melanoma) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2035

Uveal Melanoma Treatment Market Outlook 2035

The global uveal melanoma treatment market size was valued at US$ 1.2 Billion in 2024 and is projected to reach US$ 2.5 Billion by 2035, expanding at a CAGR of 7.1% from 2025 to 2035. The market growth is driven by the rising incidence of uveal melanoma, improved diagnostic technologies, technological advancements in precision medicine, and a supportive regulatory environment for rare diseases.

Market Size & Highlights

The uveal melanoma treatment market reached US$ 1.2 Billion in 2024.
The market is expected to climb to US$ 2.5 Billion by 2035.
The industry is anticipated to expand at a CAGR of 7.1% from 2025 to 2035.
Top companies in the market include Novartis AG, Pfizer Inc., IDEAYA Biosciences, Inc. and Eli Lilly and Company
North America dominated the market in 2024, holding the largest revenue share of 44.2%.
By Therapy Type, the Radiation Therapies segment held the major market share of 39.7% in 2024.

Uveal Melanoma Treatment Market By Region

Analysts’ Viewpoint regarding Uveal Melanoma Treatment Market

Increased diagnostic accuracy and wider availability of high-end ocular imaging are significant drivers to the uveal melanoma treatment market. High-resolution optical coherence tomography, multimodal fundus imaging, and enhanced MRI and ultrasound interpretation allow for precise staging after earlier diagnosis, thereby increasing the number of patients eligible for treatment.

Concomitant improvement in liquid biopsy utility and pathology workflows boosts streamlines clinical pathways and diagnostic confidence. Augmented with increasing private and public funding in ophthalmic oncology facilities, these innovations drive adoption of established and emerging treatments.

Supportive regulatory landscape and favorable reimbursement systems are further driving the uveal melanoma treatment market. These factors contribute to streamlined clinical trial design strategies, adaptive designs, and accelerated-review processes, thereby shortening time-to-market and decreasing sponsors' development risk. Payers’ acceptance of value-based outcomes coupled with expansion of coverage for advanced ocular procedures are driving the adoption of next-generation radiotherapy treatments and high-cost modalities.

Furthermore, improved coordination amongst specialty clinics, academic institutions, and contract research organizations optimizes trial enrollment. This integrated ecosystem not only strengthens the commercial predictability but also appeals to a wider base of diversified capital investors into the market.

An ongoing market trend is a paradigm shift to multimodal therapeutic strategies, as well as the innovation of delivery platforms that are adapted to ocular anatomy. Furthermore, there are localized intravitreal and intraocular delivery systems, more precise radiation dosimetry, and ophthalmic drug conjugates, aimed at achieving organ-preserving outcomes.

Concurrently, at a wider scale, research is being conducted about systemic therapies, which can be used along with regional liver-directed interventions for metastatic control. Besides, there has been a substantial increase in the funding for real-world evidence production and patient-reported outcome measurement. Hence, it has turned out to be more convenient for the stakeholders to assess the functional benefit, thereby affecting payer decisions and clinical guideline revisions.

The competitive landscape is heavily shaped by strategic alliances, licensing agreements, and focused R&D investments that aim to differentiate ophthalmic oncology portfolios. For example, In September 2025, IDEAYA Biosciences and Servier entered into an exclusive licensing agreement for Darovasertib in uveal melanoma, underlining the importance of global partnerships in rare‑disease segment.

Uveal Melanoma Treatment Market Introduction

Uveal melanoma is a rare and an aggressive form of cancer that occurs in the uveal tract of the eye. The pigment-producing cells called melanocytes are the origin of these tumors, and is the most frequent adult primary intraocular malignancy. Although the tumor is initially confined to eyes, uveal melanoma is highly prone to metastasis, particularly to the liver, posing significant challenges for long-term survival and management.

The patient’s tumor size, site, and visual outcome serve as a basis for treatment of uveal melanoma. Medications in the form of radiotherapy, especially plaque brachytherapy and proton beam therapy, are preferred for small and intermediate tumours, as it allows preservation of eyes. Surgeries like local resection or enucleation are for large or virulent melanomas which are not responsive to radiotherapy.

Systemic therapies are gradually gaining importance, particularly for metastatic or unresectable conditions. Immune-based therapies, targeted drugs, and liver-directed treatments are delivered to haul the spread of the disease, as well as to prolong survival. The approval of novel immunotherapeutic agents has marked significant progress in the management of advanced cases.

Attribute	Detail
Uveal Melanoma Treatment Market Drivers	Rising Prevalence of Eye Cancer Advances in Personalized Medicine

Rising Prevalence of Eye Cancer is Bolstering the Uveal Melanoma Treatment Market Share

The rising rate of eye cancers such as uveal melanoma is one of the primary drivers to the uveal melanoma treatment market. With improved diagnostic technology and increased awareness, an increasing number of cases are being detected at an early stage, hence the number of patients requiring medical intervention is growing. The increased occurrence causes a higher demand for effective treatments, which, in turn, prompts healthcare providers and pharmaceutical companies to raise the service capacity and make new therapy-related investments.

With rise in the number of patients, more ophthalmic oncology centers and specialty diagnostic facilities have opened, which use advanced biopsy technologies and imaging to support early diagnosis and planning for treatment. The development of clinical trials, as well as the authorization of medications that go beyond expectations, constitute the primary factors of market growth. These favorable progressions inspire a lot of other investors and business allies for providing more treatment access and better healthcare quality.

In conclusion, the increased incidence of eye cancer not only deepens the clinical significance of uveal melanoma treatment but also substantially contributes to advancement of technologies, commitment of investors, and successful marketing of therapeutic products in the global market.

Advancements in Personalized Medicine is Fostering the Uveal Melanoma Treatment Market Share

The advancements in personalized medicine are another considerable factor contributing to the expansion of the uveal melanoma treatment market. Physicians can tailor treatment utilizing deeper understanding of cancer genetics and the molecular mechanisms involved. The use of gene expression analysis and molecular profiling allows more accurate identification of tumor subtypes, which, in turn, permits the use of treatment drugs that specifically target the identified mutations or related pathways, leading to improved efficacy and lowered side effects.

Biomarker-guided diagnosis is a significant addition that has allowed the possibility of predicting the progression of disease and response to treatment with higher accuracy. Genomic assays assessing mutations in GNAQ, GNA11, and BAP1 genes has become instrumental in guiding clinical decision-making. Such personalized diagnostic tools visibly raise the possibility of early intervention and hence treatment optimization, resulting in better outcomes and survival rates.

Pharmaceutical and biotechnology companies are increasingly developing immunotherapies and targeted therapies designed for specific patient populations. Such precision-based drug development lowers the trial and error prescribing, improves regulatory success rates, and enhances commercial potential. Besides, this change in dynamics also supports a value-based healthcare model, which focuses on benefits that are quantifiable for the patient.

Radiation Therapies Leading Global Uveal Melanoma Treatment Market

Uveal Melanoma Treatment Market By Type

Uveal melanoma treatment market is dominated by the radiation therapies segment, which is considered the most effective way to control the tumor locally while preserving eye and vision. Methods like plaque brachytherapy and proton beam therapy provide accurate targeting of malignant tissues, leading to least possible injury to surrounding normal ocular structures.

Moreover, a rising preference for eye-conserving procedures and development of radiation delivery instruments have contributed to the increase in clinical acceptance of radiation therapy. A better safety profile, high success rates, and favorable reimbursement strategies have made radiation therapy the most frequently opted treatment modality for small and medium-sized uveal melanomas.

Regional Outlook of Uveal Melanoma Treatment Market

Uveal Melanoma Treatment Market By Revenue

Attribute	Detail
Leading Region	North America

As per the latest uveal melanoma treatment market analysis, North America dominated in 2024, capturing a market share of 44.2%. A well-developed healthcare system, high utilization of advanced diagnostic technologies, and a well-established network of cancer centers that are specialized in rare disease management are the key factors attributing to the region’s dominance in the global market. The region benefits with early disease detection, access to targeted therapy and a well-established reimbursement framework that supports the use of novel and high-priced therapies.

Moreover, the North America’s considerable investment in R&D, vibrant clinical trial networks, and regulatory support, create an environment for rapid paced introduction of new therapies in the market. The synergy between universities, biotech companies, and hospitals further strengthens the position of North America as the leader in the uveal melanoma treatment market.

Analysis of Key Players in Uveal Melanoma Treatment Market

The firms that are operating in the uveal melanoma treatment market are pursuing strategic collaborations, aligned drug development, and expandable clinical trials. These companies are nurturing biomarker-based research, new immunotherapies, and individualized treatment approaches - all at the same time, while they employ collaborations for enlarged access, regulatory fast-tracking, and patient assistance programs to facilitate global market access.

Novartis AG, Pfizer Inc., IDEAYA Biosciences, Inc., Eli Lilly and Company, Immunocore Ltd., Bristol-Myers Squibb Company, Merck & Co., Inc., Aura Biosciences, Inc., AstraZeneca, Delcath Systems, Inc., TriSalus Life Sciences, Inc., Replimune Group, Inc., LES LABORATOIRES SERVIER, iOnctura, and Immatics N.V. are some of the leading players operating in the global market.

Each of these players has been profiled in the uveal melanoma treatment industry research report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Key Developments in Uveal Melanoma Treatment Market

In September 2025, IDEAYA Biosciences, Inc. and Servier agreed upon a license deal of distributing darovasertib, a highly effective drug for primary and metastatic uveal melanoma to the patients worldwide. As per the agreement, Servier has acquired the rights of marketing and regulating darovasertib in all the regions outside the United States. Concurrently, IDEAYA retains marketing and development rights to darovasertib in the U.S. In addition, the agreement positions IDEAYA to receive an initial payment of US$ 210 Mn and, subject to approval, potentially receive up to US$ 100 Mn of regulatory milestone payments and up to US$ 220 Mn of commercial milestone payments, in addition to royalties on net sales in all non-US regions.
In December 2024, EORTC and Immunocore revealed the first patient randomization completion of Phase 3 Adjuvant Trial in Ocular Melanoma (ATOM) to evaluate the safety and effectiveness of tebentafusp as an adjuvant therapy for uveal melanoma.

Uveal Melanoma Treatment Market Snapshot

Attribute	Detail
Size in 2024	US$ 1.2 Bn
Forecast Value in 2035	US$ 2.5 Bn
CAGR	7.1%
Forecast Period	2025-2035
Historical Data Available for	2020-2023
Quantitative Units	US$ Bn
Uveal Melanoma Treatment Market Analysis	It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, value chain analysis, and key trend analysis.
Competition Landscape	Competition Matrix Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format	Electronic (PDF) + Excel
Segmentation	Therapy Type Immunotherapy T‑cell Redirecting / Bispecific TCR Therapies Checkpoint Inhibitors Antibody Drug Conjugates Others Immunotherapies Chemotherapy Radiation Therapies Brachytherapy External Beam Proton Therapy Gamma Knife Stereotactic Surgery Treatment Approach Monotherapy Combination Therapy Location Iris Melanoma CiliaryMelanoma Choroid Melanoma Conjunctival Melanoma Stage of Disease Localized Uveal Melanoma Metastatic Uveal Melanoma End-user Hospitals and Ambulatory Surgical Centers Ophthalmology Clinics Academic and Research Centers Others (Oncology Centers, etc.)
Regions Covered	North America Europe Asia Pacific Latin America Middle East & Africa
Countries Covered	U.S. Canada Germany U.K. France Italy Spain The Netherlands China Australia India Japan South Korea ASEAN Brazil Mexico Argentina GCC Countries South Africa
Companies Profiled	Novartis AG Pfizer Inc. IDEAYA Biosciences, Inc. Eli Lilly and Company Immunocore Ltd. Bristol-Myers Squibb Company Merck & Co., Inc. Aura Biosciences, Inc. AstraZeneca Delcath Systems, Inc. TriSalus Life Sciences, Inc. Replimune Group, Inc. LES LABORATOIRES SERVIER iOnctura Immatics N.V.
Customization Scope	Available upon request
Pricing	Available upon request

Frequently Asked Questions

How big was the global uveal melanoma treatment market in 2024?

The global uveal melanoma treatment market was valued at US$ 1.2 Bn in 2024

How big will the global uveal melanoma treatment industry be in 2035?

The global uveal melanoma treatment industry is projected to reach more than US$ 2.5 Bn by the end of 2035

What are the factors driving the uveal melanoma treatment market?

The increasing incidence of eye cancer, the shift toward personalized medicine through advanced therapies like immunotherapies and targeted drugs, accelerating regulatory approvals for rare cancers, and advances in diagnostic imaging are some of the factors driving the expansion of uveal melanoma treatment market.

What will be the CAGR of the global uveal melanoma treatment industry during the forecast period?

The CAGR is anticipated to be 7.1% from 2025 to 2035

Who are the prominent players in the global uveal melanoma treatment market?

Preface
- Market Definition and Scope
- Market Segmentation
- Key Research Objectives
- Research Highlights
Assumptions and Research Methodology
Executive Summary: Global Uveal Melanoma Treatment Market
Market Overview
- Introduction
  - Segment Definition
- Overview
- Market Dynamics
  - Drivers
  - Restraints
  - Opportunities
- Global Uveal Melanoma Treatment Market Analysis and Forecast, 2020 - 2035
  - Market Revenue Projections (US$ Bn)
Key Insights
- Healthcare Expenditure across Key Regions / Countries
- Technological Advancements in Uveal Melanoma Treatment
- Clinical Trial Analysis
- Regulatory Scenario across Key Regions / Countries
- Reimbursement Landscape across Key Regions / Countries
- PORTER’s Five Forces Analysis
- PESTLE Analysis
- Go-to-Market Strategy for New Market Entrants
- Key Purchase Metrics for End-users
- Key Industry Events (Partnership, Collaborations, Product approvals, merger & acquisitions)
- Benchmarking of the Products Offered by the Leading Competitors
Global Uveal Melanoma Treatment Market Analysis and Forecast, by Therapy Type
- Introduction & Definition
- Key Findings/Developments
- Market Value Forecast, by Therapy Type, 2020 - 2035
  - Immunotherapy
    - T cell Redirecting / Bispecific TCR Therapies
    - Checkpoint Inhibitors
    - Antibody Drug Conjugates
    - Others Immunotherapies
  - Chemotherapy
  - Radiation Therapies
    - Brachytherapy
    - External Beam Proton Therapy
    - Gamma Knife Stereotactic Surgery
- Market Attractiveness Analysis, by Therapy Type
Global Uveal Melanoma Treatment Market Analysis and Forecast, by Treatment Approach
- Introduction & Definition
- Key Findings/Developments
- Market Value Forecast, by Treatment Approach, 2020 - 2035
  - Monotherapy
  - Combination Therapy
- Market Attractiveness Analysis, by Treatment Approach
Global Uveal Melanoma Treatment Market Analysis and Forecast, by Location
- Introduction & Definition
- Key Findings/Developments
- Market Value Forecast, by Location, 2020 - 2035
  - Iris Melanoma
  - Ciliary Melanoma
  - Choroid Melanoma
  - Conjunctival Melanoma
- Market Attractiveness Analysis, by Location
Global Uveal Melanoma Treatment Market Analysis and Forecast, by Stage of Disease
- Introduction & Definition
- Key Findings/Developments
- Market Value Forecast, by Stage of Disease, 2020 - 2035
  - Localized Uveal Melanoma
  - Metastatic Uveal Melanoma
- Market Attractiveness Analysis, by Stage of Disease
Global Uveal Melanoma Treatment Market Analysis and Forecast, by End-user
- Introduction & Definition
- Key Findings/Developments
- Market Value Forecast, by End-user, 2020 - 2035
  - Hospitals and Ambulatory Surgical Centers
  - Ophthalmology Clinics
  - Academic and Research Centers
  - Others
- Market Attractiveness Analysis, by End-user
Global Uveal Melanoma Treatment Market Analysis and Forecast, by Region
- Key Findings
- Market Value Forecast, by Region, 2020 - 2035
  - North America
  - Europe
  - Asia Pacific
  - Latin America
  - Middle East & Africa
- Market Attractiveness Analysis, by Region
North America Uveal Melanoma Treatment Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Therapy Type, 2020 - 2035
  - Immunotherapy
    - T cell Redirecting / Bispecific TCR Therapies
    - Checkpoint Inhibitors
    - Antibody Drug Conjugates
    - Others Immunotherapies
  - Chemotherapy
  - Radiation Therapies
    - Brachytherapy
    - External Beam Proton Therapy
    - Gamma Knife Stereotactic Surgery
- Market Value Forecast, by Treatment Approach, 2020 - 2035
  - Monotherapy
  - Combination Therapy
- Market Value Forecast, by Location, 2020 - 2035
  - Iris Melanoma
  - Ciliary Melanoma
  - Choroid Melanoma
  - Conjunctival Melanoma
- Market Value Forecast, by Stage of Disease, 2020 - 2035
  - Localized Uveal Melanoma
  - Metastatic Uveal Melanoma
- Market Value Forecast, by End-user, 2020 - 2035
  - Hospitals and Ambulatory Surgical Centers
  - Ophthalmology Clinics
  - Academic and Research Centers
  - Others
- Market Value Forecast, by Country, 2020 - 2035
  - U.S.
  - Canada
- Market Attractiveness Analysis
  - By Therapy Type
  - By Treatment Approach
  - By Location
  - By Stage of Disease
  - By End-user
  - By Country
Europe Uveal Melanoma Treatment Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Therapy Type, 2020 - 2035
  - Immunotherapy
    - T cell Redirecting / Bispecific TCR Therapies
    - Checkpoint Inhibitors
    - Antibody Drug Conjugates
    - Others Immunotherapies
  - Chemotherapy
  - Radiation Therapies
    - Brachytherapy
    - External Beam Proton Therapy
    - Gamma Knife Stereotactic Surgery
- Market Value Forecast, by Treatment Approach, 2020 - 2035
  - Monotherapy
  - Combination Therapy
- Market Value Forecast, by Location, 2020 - 2035
  - Iris Melanoma
  - Ciliary Melanoma
  - Choroid Melanoma
  - Conjunctival Melanoma
- Market Value Forecast, by Stage of Disease, 2020 - 2035
  - Localized Uveal Melanoma
  - Metastatic Uveal Melanoma
- Market Value Forecast, by End-user, 2020 - 2035
  - Hospitals and Ambulatory Surgical Centers
  - Ophthalmology Clinics
  - Academic and Research Centers
  - Others
- Market Value Forecast, by Country/Sub-region, 2020 - 2035
  - UK
  - Germany
  - France
  - Italy
  - Spain
  - The Netherlands
  - Rest of Europe
- Market Attractiveness Analysis
  - By Therapy Type
  - By Treatment Approach
  - By Location
  - By Stage of Disease
  - By End-user
  - By Country/Sub-region
Asia Pacific Uveal Melanoma Treatment Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Therapy Type, 2020 - 2035
  - Immunotherapy
    - T cell Redirecting / Bispecific TCR Therapies
    - Checkpoint Inhibitors
    - Antibody Drug Conjugates
    - Others Immunotherapies
  - Chemotherapy
  - Radiation Therapies
    - Brachytherapy
    - External Beam Proton Therapy
    - Gamma Knife Stereotactic Surgery
- Market Value Forecast, by Treatment Approach, 2020 - 2035
  - Monotherapy
  - Combination Therapy
- Market Value Forecast, by Location, 2020 - 2035
  - Iris Melanoma
  - Ciliary Melanoma
  - Choroid Melanoma
  - Conjunctival Melanoma
- Market Value Forecast, by Stage of Disease, 2020 - 2035
  - Localized Uveal Melanoma
  - Metastatic Uveal Melanoma
- Market Value Forecast, by End-user, 2020 - 2035
  - Hospitals and Ambulatory Surgical Centers
  - Ophthalmology Clinics
  - Academic and Research Centers
  - Others
- Market Value Forecast, by Country/Sub-region, 2020 - 2035
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
- Market Attractiveness Analysis
  - By Therapy Type
  - By Treatment Approach
  - By Location
  - By Stage of Disease
  - By End-user
  - By Country/Sub-region
Latin America Uveal Melanoma Treatment Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Therapy Type, 2020 - 2035
  - Immunotherapy
    - T cell Redirecting / Bispecific TCR Therapies
    - Checkpoint Inhibitors
    - Antibody Drug Conjugates
    - Others Immunotherapies
  - Chemotherapy
  - Radiation Therapies
    - Brachytherapy
    - External Beam Proton Therapy
    - Gamma Knife Stereotactic Surgery
- Market Value Forecast, by Treatment Approach, 2020 - 2035
  - Monotherapy
  - Combination Therapy
- Market Value Forecast, by Location, 2020 - 2035
  - Iris Melanoma
  - Ciliary Melanoma
  - Choroid Melanoma
  - Conjunctival Melanoma
- Market Value Forecast, by Stage of Disease, 2020 - 2035
  - Localized Uveal Melanoma
  - Metastatic Uveal Melanoma
- Market Value Forecast, by End-user, 2020 - 2035
  - Hospitals and Ambulatory Surgical Centers
  - Ophthalmology Clinics
  - Academic and Research Centers
  - Others
- Market Value Forecast, by Country/Sub-region, 2020 - 2035
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
- Market Attractiveness Analysis
  - By Therapy Type
  - By Treatment Approach
  - By Location
  - By Stage of Disease
  - By End-user
  - By Country/Sub-region
Middle East & Africa Uveal Melanoma Treatment Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Therapy Type, 2020 - 2035
  - Immunotherapy
    - T cell Redirecting / Bispecific TCR Therapies
    - Checkpoint Inhibitors
    - Antibody Drug Conjugates
    - Others Immunotherapies
  - Chemotherapy
  - Radiation Therapies
    - Brachytherapy
    - External Beam Proton Therapy
    - Gamma Knife Stereotactic Surgery
- Market Value Forecast, by Treatment Approach, 2020 - 2035
  - Monotherapy
  - Combination Therapy
- Market Value Forecast, by Location, 2020 - 2035
  - Iris Melanoma
  - Ciliary Melanoma
  - Choroid Melanoma
  - Conjunctival Melanoma
- Market Value Forecast, by Stage of Disease, 2020 - 2035
  - Localized Uveal Melanoma
  - Metastatic Uveal Melanoma
- Market Value Forecast, by End-user, 2020 - 2035
  - Hospitals and Ambulatory Surgical Centers
  - Ophthalmology Clinics
  - Academic and Research Centers
  - Others
- Market Value Forecast, by Country/Sub-region, 2020 - 2035
  - GCC Countries
  - South Africa
  - Rest of Middle East & Africa
- Market Attractiveness Analysis
  - By Therapy Type
  - By Treatment Approach
  - By Location
  - By Stage of Disease
  - By End-user
  - By Country/Sub-region
Competition Landscape
- Market Player - Competition Matrix (By Tier and Size of Companies)
- Market Share Analysis, by Company (2024)
- Company Profiles
  - Novartis AG
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Pfizer Inc.
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - IDEAYA Biosciences, Inc.
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Eli Lilly and Company
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Immunocore Ltd.
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Bristol-Myers Squibb Company
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Merck & Co., Inc.
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Aura Biosciences, Inc.
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - AstraZeneca
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Delcath Systems, Inc.
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - TriSalus Life Sciences, Inc.
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Replimune Group, Inc.
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - LES LABORATOIRES SERVIER
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - iOnctura
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Immatics N.V.
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Other Prominent Players

List of Tables

Table 01: Global Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By Therapy Type, 2020 to 2035
Table 02: Global Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By Immunotherapy, 2020 to 2035
Table 03: Global Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By Radiation Therapies, 2020 to 2035
Table 04: Global Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By Treatment Approach, 2020 to 2035
Table 05: Global Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By Location, 2020 to 2035
Table 06: Global Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By Stage of Disease, 2020 to 2035
Table 07: Global Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 08: Global Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By Region, 2020 to 2035
Table 09: North America Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, by Country, 2020-2035
Table 10: North America Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By Therapy Type, 2020 to 2035
Table 11: North America Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By Immunotherapy, 2020 to 2035
Table 12: North America Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By Radiation Therapies, 2020 to 2035
Table 13: North America Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By Treatment Approach, 2020 to 2035
Table 14: North America Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By Location, 2020 to 2035
Table 15: North America Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By Stage of Disease, 2020 to 2035
Table 16: North America Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 17: Europe Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2035
Table 18: Europe Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By Therapy Type, 2020 to 2035
Table 19: Europe Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By Immunotherapy, 2020 to 2035
Table 20: Europe Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By Radiation Therapies, 2020 to 2035
Table 21: Europe Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By Treatment Approach, 2020 to 2035
Table 22: Europe Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By Location, 2020 to 2035
Table 23: Europe Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By Stage of Disease, 2020 to 2035
Table 24: Europe Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 25: Asia Pacific Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2035
Table 26: Asia Pacific Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By Therapy Type, 2020 to 2035
Table 27: Asia Pacific Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By Immunotherapy, 2020 to 2035
Table 28: Asia Pacific Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By Radiation Therapies, 2020 to 2035
Table 29: Asia Pacific Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By Treatment Approach, 2020 to 2035
Table 30: Asia Pacific Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By Location, 2020 to 2035
Table 31: Asia Pacific Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By Stage of Disease, 2020 to 2035
Table 32: Asia Pacific Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 33: Latin America Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2035
Table 34: Latin America Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By Therapy Type, 2020 to 2035
Table 35: Latin America Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By Immunotherapy, 2020 to 2035
Table 36: Latin America Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By Radiation Therapies, 2020 to 2035
Table 37: Latin America Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By Treatment Approach, 2020 to 2035
Table 38: Latin America Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By Location, 2020 to 2035
Table 39: Latin America Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By Stage of Disease, 2020 to 2035
Table 40: Latin America Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 41: Middle East & Africa Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2035
Table 42: Middle East & Africa Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By Therapy Type, 2020 to 2035
Table 43: Middle East & Africa Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By Immunotherapy, 2020 to 2035
Table 44: Middle East & Africa Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By Radiation Therapies, 2020 to 2035
Table 45: Middle East & Africa Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By Treatment Approach, 2020 to 2035
Table 46: Middle East & Africa Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By Location, 2020 to 2035
Table 47: Middle East & Africa Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By Stage of Disease, 2020 to 2035
Table 48: Middle East & Africa Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035

List of Figures

Figure 01: Global Uveal Melanoma Treatment Market Value Share Analysis, By Therapy Type, 2024 and 2035
Figure 02: Global Uveal Melanoma Treatment Market Attractiveness Analysis, By Therapy Type, 2025 to 2035
Figure 03: Global Uveal Melanoma Treatment Market Revenue (US$ Bn), by Immunotherapy, 2020 to 2035
Figure 04: Global Uveal Melanoma Treatment Market Revenue (US$ Bn), by Chemotherapy, 2020 to 2035
Figure 05: Global Uveal Melanoma Treatment Market Revenue (US$ Bn), by Radiation Therapies, 2020 to 2035
Figure 06: Global Uveal Melanoma Treatment Market Value Share Analysis, By Treatment Approach, 2024 and 2035
Figure 07: Global Uveal Melanoma Treatment Market Attractiveness Analysis, By Treatment Approach, 2025 to 2035
Figure 08: Global Uveal Melanoma Treatment Market Revenue (US$ Bn), by Monotherapy, 2020 to 2035
Figure 09: Global Uveal Melanoma Treatment Market Revenue (US$ Bn), by Combination Therapy, 2020 to 2035
Figure 10: Global Uveal Melanoma Treatment Market Value Share Analysis, By Location, 2024 and 2035
Figure 11: Global Uveal Melanoma Treatment Market Attractiveness Analysis, By Location, 2025 to 2035
Figure 12: Global Uveal Melanoma Treatment Market Revenue (US$ Bn), by Iris Melanoma, 2020 to 2035
Figure 13: Global Uveal Melanoma Treatment Market Revenue (US$ Bn), by Ciliary Melanoma, 2020 to 2035
Figure 14: Global Uveal Melanoma Treatment Market Revenue (US$ Bn), by Choroid Melanoma, 2020 to 2035
Figure 15: Global Uveal Melanoma Treatment Market Revenue (US$ Bn), by Conjunctival Melanoma, 2020 to 2035
Figure 16: Global Uveal Melanoma Treatment Market Value Share Analysis, By Stage of Disease, 2024 and 2035
Figure 17: Global Uveal Melanoma Treatment Market Attractiveness Analysis, By Stage of Disease, 2025 to 2035
Figure 18: Global Uveal Melanoma Treatment Market Revenue (US$ Bn), by Localized Uveal Melanoma, 2020 to 2035
Figure 19: Global Uveal Melanoma Treatment Market Revenue (US$ Bn), by Metastatic Uveal Melanoma, 2020 to 2035
Figure 20: Global Uveal Melanoma Treatment Market Value Share Analysis, By End-user, 2024 and 2035
Figure 21: Global Uveal Melanoma Treatment Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 22: Global Uveal Melanoma Treatment Market Revenue (US$ Bn), by Hospitals and Ambulatory Surgical Centers, 2020 to 2035
Figure 23: Global Uveal Melanoma Treatment Market Revenue (US$ Bn), by Ophthalmology Clinics, 2020 to 2035
Figure 24: Global Uveal Melanoma Treatment Market Revenue (US$ Bn), Academic and Research Centers, 2020 to 2035
Figure 25: Global Uveal Melanoma Treatment Market Revenue (US$ Bn), by Others, 2020 to 2035
Figure 26: Global Uveal Melanoma Treatment Market Value Share Analysis, By Region, 2024 and 2035
Figure 27: Global Uveal Melanoma Treatment Market Attractiveness Analysis, By Region, 2025 to 2035
Figure 28: North America Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 29: North America Uveal Melanoma Treatment Market Value Share Analysis, by Country, 2024 and 2035
Figure 30: North America Uveal Melanoma Treatment Market Attractiveness Analysis, by Country, 2025 to 2035
Figure 31: North America Uveal Melanoma Treatment Market Value Share Analysis, By Therapy Type, 2024 and 2035
Figure 32: North America Uveal Melanoma Treatment Market Attractiveness Analysis, By Therapy Type, 2025 to 2035
Figure 33: North America Uveal Melanoma Treatment Market Value Share Analysis, By Treatment Approach, 2024 and 2035
Figure 34: North America Uveal Melanoma Treatment Market Attractiveness Analysis, By Treatment Approach, 2025 to 2035
Figure 35: North America Uveal Melanoma Treatment Market Value Share Analysis, By Location, 2024 and 2035
Figure 36: North America Uveal Melanoma Treatment Market Attractiveness Analysis, By Location, 2025 to 2035
Figure 37: North America Uveal Melanoma Treatment Market Value Share Analysis, By Stage of Disease, 2024 and 2035
Figure 38: North America Uveal Melanoma Treatment Market Attractiveness Analysis, By Stage of Disease, 2025 to 2035
Figure 39: North America Uveal Melanoma Treatment Market Value Share Analysis, By End-user, 2024 and 2035
Figure 40: North America Uveal Melanoma Treatment Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 41: Europe Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 42: Europe Uveal Melanoma Treatment Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
Figure 43: Europe Uveal Melanoma Treatment Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
Figure 44: Europe Uveal Melanoma Treatment Market Value Share Analysis, By Therapy Type, 2024 and 2035
Figure 45: Europe Uveal Melanoma Treatment Market Attractiveness Analysis, By Therapy Type, 2025 to 2035
Figure 46: Europe Uveal Melanoma Treatment Market Value Share Analysis, By Treatment Approach, 2024 and 2035
Figure 47: Europe Uveal Melanoma Treatment Market Attractiveness Analysis, By Treatment Approach, 2025 to 2035
Figure 48: Europe Uveal Melanoma Treatment Market Value Share Analysis, By Location, 2024 and 2035
Figure 49: Europe Uveal Melanoma Treatment Market Attractiveness Analysis, By Location, 2025 to 2035
Figure 50: Europe Uveal Melanoma Treatment Market Value Share Analysis, By Stage of Disease, 2024 and 2035
Figure 51: Europe Uveal Melanoma Treatment Market Attractiveness Analysis, By Stage of Disease, 2025 to 2035
Figure 52: Europe Uveal Melanoma Treatment Market Value Share Analysis, By End-user, 2024 and 2035
Figure 53: Europe Uveal Melanoma Treatment Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 54: Asia Pacific Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 55: Asia Pacific Uveal Melanoma Treatment Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
Figure 56: Asia Pacific Uveal Melanoma Treatment Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
Figure 57: Asia Pacific Uveal Melanoma Treatment Market Value Share Analysis, By Therapy Type, 2024 and 2035
Figure 58: Asia Pacific Uveal Melanoma Treatment Market Attractiveness Analysis, By Therapy Type, 2025 to 2035
Figure 59: Asia Pacific Uveal Melanoma Treatment Market Value Share Analysis, By Treatment Approach, 2024 and 2035
Figure 60: Asia Pacific Uveal Melanoma Treatment Market Attractiveness Analysis, By Treatment Approach, 2025 to 2035
Figure 61: Asia Pacific Uveal Melanoma Treatment Market Value Share Analysis, By Location, 2024 and 2035
Figure 62: Asia Pacific Uveal Melanoma Treatment Market Attractiveness Analysis, By Location, 2025 to 2035
Figure 63: Asia Pacific Uveal Melanoma Treatment Market Value Share Analysis, By Stage of Disease, 2024 and 2035
Figure 64: Asia Pacific Uveal Melanoma Treatment Market Attractiveness Analysis, By Stage of Disease, 2025 to 2035
Figure 65: Asia Pacific Uveal Melanoma Treatment Market Value Share Analysis, By End-user, 2024 and 2035
Figure 66: Asia Pacific Uveal Melanoma Treatment Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 67: Latin America Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 68: Latin America Uveal Melanoma Treatment Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
Figure 69: Latin America Uveal Melanoma Treatment Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
Figure 70: Latin America Uveal Melanoma Treatment Market Value Share Analysis, By Therapy Type, 2024 and 2035
Figure 71: Latin America Uveal Melanoma Treatment Market Attractiveness Analysis, By Therapy Type, 2025 to 2035
Figure 72: Latin America Uveal Melanoma Treatment Market Value Share Analysis, By Treatment Approach, 2024 and 2035
Figure 73: Latin America Uveal Melanoma Treatment Market Attractiveness Analysis, By Treatment Approach, 2025 to 2035
Figure 74: Latin America Uveal Melanoma Treatment Market Value Share Analysis, By Location, 2024 and 2035
Figure 75: Latin America Uveal Melanoma Treatment Market Attractiveness Analysis, By Location, 2025 to 2035
Figure 76: Latin America Uveal Melanoma Treatment Market Value Share Analysis, By Stage of Disease, 2024 and 2035
Figure 77: Latin America Uveal Melanoma Treatment Market Attractiveness Analysis, By Stage of Disease, 2025 to 2035
Figure 78: Latin America Uveal Melanoma Treatment Market Value Share Analysis, By End-user, 2024 and 2035
Figure 79: Latin America Uveal Melanoma Treatment Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 80: Middle East & Africa Uveal Melanoma Treatment Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 81: Middle East & Africa Uveal Melanoma Treatment Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
Figure 82: Middle East & Africa Uveal Melanoma Treatment Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
Figure 83: Middle East & Africa Uveal Melanoma Treatment Market Value Share Analysis, By Therapy Type, 2024 and 2035
Figure 84: Middle East & Africa Uveal Melanoma Treatment Market Attractiveness Analysis, By Therapy Type, 2025 to 2035
Figure 85: Middle East & Africa Uveal Melanoma Treatment Market Value Share Analysis, By Treatment Approach, 2024 and 2035
Figure 86: Middle East & Africa Uveal Melanoma Treatment Market Attractiveness Analysis, By Treatment Approach, 2025 to 2035
Figure 87: Middle East & Africa Uveal Melanoma Treatment Market Value Share Analysis, By Location, 2024 and 2035
Figure 88: Middle East & Africa Uveal Melanoma Treatment Market Attractiveness Analysis, By Location, 2025 to 2035
Figure 89: Middle East & Africa Uveal Melanoma Treatment Market Value Share Analysis, By Stage of Disease, 2024 and 2035
Figure 90: Middle East & Africa Uveal Melanoma Treatment Market Attractiveness Analysis, By Stage of Disease, 2025 to 2035
Figure 91: Middle East & Africa Uveal Melanoma Treatment Market Value Share Analysis, By End-user, 2024 and 2035
Figure 92: Middle East & Africa Uveal Melanoma Treatment Market Attractiveness Analysis, By End-user, 2025 to 2035